Socioeconomic and demographic characteristics of sickle cell disease patients from a low-income region of northeastern Brazil

Revista Brasileira de Hematologia e Hemoterapia

Volumn 37, Issue 3, 2015, Pages 172-177

  Fernandes, Thales Allyrio Araújo de Medeiros ^a   Medeiros, Tereza Maria Dantas de ^b   Alves, Jayra Juliana Paiva ^b   Bezerra, Christiane Medeiros ^b   Fernandes, José Veríssimo ^b   Serafim, Édvis Santos Soares ^c   Fernandes, Maria Zélia ^d   Sonati, Maria de Fatima ^e  

^a DEPARTAMENTO DE FÍSICA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c Hemocentro Dalton Barbosa Cunha   (Brazil)

^d Hospital Infantil Varela Santiago   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Anemia; Hydroxyurea; Penicillin; Sickle cell; Socioeconomic factors; Vaccination

Indexed keywords

HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; MENINGOCOCCUS VACCINE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BETA THALASSEMIA; BRAZIL; CAREGIVER; CHILD; CROSS-SECTIONAL STUDY; EDUCATION; FEMALE; HUMAN; IMMUNIZATION; INFANT; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULATTO; OUTPATIENT; QUESTIONNAIRE; SCHOOL CHILD; SICKLE CELL ANEMIA; SOCIOECONOMICS;

EID: 84930082667     PISSN: 15168484     EISSN: 18060870     Source Type: Journal    
DOI: 10.1016/j.bjhh.2015.03.013     Document Type: Article

References (34)

1. Rees D.C., Williams T.N., Gladwin M.T. Sickle-cell disease. Lancet 2010, 376(9757):2018-2031.
2. Steinberg M. Sickle cell disease. Disorders of hemoglobin - genetics, pathophysiology and clinical management 2009, 435-436. Cambridge University Press, 2nd ed. Cambridge. M. Steinberg, B. Forget, D. Higgs, D. Weatheral (Eds.).
3. Steinberg M.H., Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol 2012, 87(8):795-803.
4. Piel F.B., Hay S.I., Gupta S., Weatherall D.J., Williams T.N. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med 2013, 10(7):e1001484.
5. Cançado R.D., Jesus J.A. A doença falciforme no Brasil. Rev Bras Hematol Hemoter 2007, 29(3):204-206.
6. Ballas S.K., Kesen M.R., Goldberg M.F., Lutty G.A., Dampier C., Osunkwo I., et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal 2012, 2012:949535.
7. Pereira S.A., Brener S., Cardoso C.S., Proietti A.B. Sickle cell disease: quality of life in patients with hemoglobin SS and SC disorders. Rev Bras Hematol Hemoter 2013, 35(5):325-331.
8. Santos J.P., Gomes Neto M. Sociodemographic aspects and quality of life of patients with sickle cell anemia. Rev Bras Hematol Hemoter 2013, 35(4):242-245.
9. Paiva e Silva R.B., Ramalho A.S., Cassorla R.M. Sickle cell disease as a public health problem in Brazil. Rev Saude Publica 1993, 27(1):54-58.
10. Nações Unidas Ranking IDHM Unidades da Federação 2010. Available from: [cited 30.01.15]. http://www.pnud.org.br/atlas/ranking/Ranking-IDHM-UF-2010.aspx.
11. Instituto Brasileiro de Geografia e Estatística - IBGE Síntese de indicadores sociais-uma análise das condições de vida da população brasileira 2014, IBGE, Rio de Janeiro, 214 pp.
12. Maximo C. The policy for comprehensive care of persons with sickle cell disease in Rio de Janeiro and the challenge of decentralization 2009, [thesis], Rio de janeiro: Fundação Oswaldo Cruz - Escola Nacional de Saude Publica, 104 pp.
13. Cascudo L.C. História do Rio Grande do Norte 1955, Departamento de Imprensa Nacional, Rio de Janeiro.
14. Brousseau D.C., Panepinto J.A., Nimmer M., Hoffmann R.G. The number of people with sickle-cell disease in the United States - national and state estimates. Am J Hematol 2010, 85(1):77-78.
15. Aljuburi G., Laverty A.A., Green S.A., Phekoo K.J., Bell D., Majeed A. Socio-economic deprivation and risk of emergency readmission and inpatient mortality in people with sickle cell disease in England: observational study. J Public Health 2013, 35(4):510-517.
16. McCavit T.L., Lin H., Zhang S., Ahn C., Quinn C.T., Flores G. Hospital volume, hospital teaching status, patient socioeconomic status, and outcomes in patients hospitalized with sickle cell disease. Am J Hematol 2011, 86(4):377-380.
17. Adegoke S.A., Adeodu O.O., Adekile A.D. Sickle cell disease clinical phenotypes in children from South-Western, Nigeria. Niger J Clin Pract 2015, 18(1):95-101.
18. Felix A.A., Souza H.M. Epidemiologic, Ribeiro S.B. social aspects of sickle cell disease. Rev Bras Hematol Hemoter 2010, 32(3):203-208.
19. Loureiro M.M., Rozenfeld S., Portugal R.D. Acute clinical events in patients with sickle cell disease: epidemiology and treatment. Rev Bras Hematol Hemoter 2008, 30(2):95-100.
20. Reiners A.A., Azevedo R.C., Vieira M.A., de Arruda A.L. Bibliographic production about adherence/non-adherence to therapy. Cien Saude Colet 2008, 13(Suppl. 2):2299-2306.
21. McGann P.T., Nero A.C., Ware R.E. Current management of sickle cell anemia. Cold Spring Harb Perspect Med 2013, 3(8). pii: a011817.
22. Silva Junior G.B., Libório A.B., Vieira A.P., Bem A.X., Lopes Filho A.S., Figueiredo Filho A.C., et al. Evaluation of renal function in sickle cell disease patients in Brazil. Braz J Med Biol Res 2012, 45(7):652-655.
23. Brandow A.M., Jirovec D.L., Penepinto J.A. Hydroxyurea in children with sickle cell disease - practice patterns and barriers to utilization. Am J Hematol 2010, 85(8):611-613.
24. Zumberg M.S., Reddy S., Boyette R.L., Schwartz R.J., Konrad T.R., Lottenberg R. Hydroxyurea therapy for sickle cell disease in community-based practices - a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol 2005, 79:107-113.
25. Thornburg C.D., Files B.A., Luo Z., Miller S.T., Kalpatthi R., Iyer R., et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012, 120(22):4304-4310.
26. Gaston M.H., Verter J.I., Woods G., Pegelow C., Kelleher J., Presburry G., et al. Prophylaxis with oral penicillin in children with sickle cell anemia A randomized trial. N Engl J Med 1986, 314(25):1593-1599.
27. Halasa N.B., Shankar S.M., Talbot T.R., Arbogast P.G., Mitchel E.F., Wang W.C., et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007, 44(11):1428-1433.
28. Frauches D.O., Matos P.A., Vatanabe J.H., Oliveira J.F., Lima A.P., Moreira-Silva S.F. Vaccination against pneumococcus in children with sickle cell anemia in the state of Espirito Santo, Brazil, between 2004 and 2007. Epidemiol Serv Saude 2010, 19(2):165-172.
29. Hardie R., King L., Fraser R., Reid M. Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening. Ann Trop Paediatr 2009, 29(3):197-202.
30. Warren M.D., Arbogast P.G., Dudley J.A., Kaltenbach L., Ray W.A., Wang W.C., et al. Adherlatic antibiotic guidelines among Medicaid infants with sickle cell disease. Arch Pediatr Adolesc Med 2010, 164(3):298-299.
31. Gomes L.M., Reis T.C., Vieira M.M., de Andrade-Barbosa T.L., Caldeira A.P. Quality of assistance provided to children with sickle cell disease by primary healthcare services. Rev Bras Hematol Hemoter 2011, 33(4):277-282.
32. King L., Ali S., Knight-Madden J., MooSang M., Reid M. Compliance with intramuscular penicillin prophylaxis in children with sickle cell disease in Jamaica. West Indian Med J 2011, 60(2):177-180.
33. Wolfson J.A., Schrager S.M., Khanna R., Coates T.D., Kipke M.D. Sickle cell disease in California: sociodemographic predictors of emergency department utilization. Pediatr Blood Cancer 2012, 58(1):66-73.
34. Fernandes A.P., Viana M.B. Caracterização e circunstâncias da ocorrência de óbitos em crianças com doença falciforme triadas pelo Programa Estadual de Triagem Neonatal de Minas Gerais, no período de março de 1998 a fevereiro de 2007, [thesis], Universidade Federal de Minas Gerais, Belo Horizonte, 82 pp.